Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
Aclaris Therapeutics priced a $50.0 million underwritten offering of 7,785,714 common shares at $3.50 per share plus pre-funded warrants on 6,500,000 shares. Existing life-science investors TCGX, RA Capital Management, Invus, and a large mutual fund are participating, with closing expected October 28, 2026.
Key figures
- Deal Value Usd
- 50000000
- Offering Price
- 3.5
- Shares Offered
- 7785714
- Pre funded warrant price
- 3.49999
- Pre funded warrant shares
- 6500000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.